Strategies for Determining Critical Quality Attributes of Nucleic Acid Therapeutics and Their Carriers

Determining the critical quality attributes (CQAs) of emerging, more complex nucleic acid (NA) therapeutics and their carrier systems poses a new challenge for biopharmaceutical companies. Low molecular weight NA therapeutics, such as antisense oligonucleotides or small interfering RNA, can be fully characterized using CQAs like identity or purity using many different analytical tools. However, analyzing higher molecular weight molecules such as guide RNA, messenger RNA or plasmid therapeutics remains difficult for most existing methods.

Low molecular weight NA therapeutics, such as antisense oligonucleotides or small interfering RNA, can be fully characterized regarding CQAs such as identity or purity using many different analytical tools.

In this GEN webinar, our expert speaker will discuss the advantages and limitations of current analytical techniques for determining the CQAs of NA therapeutics using examples from different NA classes. During the webinar, you’ll gain insights into how physicochemical analysis of viral and lipid-based nanoparticles can provide useful characteristics of these complex systems that are relevant for the use in therapeutics development

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.